A Study of Decreased Mental Function Associated With HIV

• Status: Completed
• Trial end date: 2005-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare pictures of the brain of HIV-infected people with memory problems before and after treatment with selegiline. Selegiline is the study drug received through A5090.

HIV patients generally develop memory problems late in the disease. This will be examined using noninvasive proton magnetic resonance spectroscopy (1H-MRS). The effect of the drug selegiline on memory problems also will be examined.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Treatments: Selegiline

Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

• Are enrolled in ACTG protocol A5090.

• Meet the inclusion/exclusion criteria set forth for the Step 1 phase of AACTG protocol A5090.

Exclusion Criteria

Patients will not be eligible for this study if they have:

• Claustrophobia (unless sedation with lorazepam or zolpidem allows for safe performance of the MRS).

• Metallic implants/medical devices (e.g., skull implants or cardiac devices).